LivaNova PLC LIVN
89.99 USD -1.15 (-1.26%)
At closeNov 6, 2026, 4:00 PM EST
89.99 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
88.42 Day range 91.51
49.57 52-week range 94.19
- YTD
- +46.25%
- 1 year
- +81.54%
News
benzinga.com Baird Maintains Outperform on LivaNova, Raises Price Target to $111 Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $95 to $111.
seekingalpha.com LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
marketbeat.com LivaNova Q3 Earnings Call Highlights LivaNova NASDAQ: LIVN reported third-quarter 2026 revenue growth of 10% from the prior-year period, driven by double-digit gains in its Cardiopulmonary and epilepsy businesses. The medical technology…
benzinga.com Needham Maintains Buy on LivaNova, Raises Price Target to $112 Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $93 to $112.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
zacks.com LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for LivaNova (LIVN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
benzinga.com Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday U.S. stocks surged, led by Wayfair after strong results; Cricut, Array Technologies, Clear Secure and others also posted double-digit gains.
zacks.com LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates LivaNova (LIVN) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.11 per share a year ago.
benzinga.com LivaNova Raises FY2026 Adj EPS Guidance from $4.30-$4.40 to $4.40-$4.50 vs $4.37 Est; Raises FY2026 Sales Guidance from $1.499B-$1.513B to $1.513B-$1.527B vs $1.522B Est LivaNova (NASDAQ:LIVN) raises FY2026 Adj EPS guidance from $4.30-$4.40 to $4.40-$4.50 vs $4.37 analyst estimate. Raises FY2026 sales outlook from $1.499 billion-$1.513 billion to $1.513…- benzinga.com LivaNova Q3 Adj. EPS $1.23 Beats $1.06 Estimate, Sales $393.100M Beat $381.067M Estimate LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.23 per share which beat the analyst consensus estimate of $1.06 by 16.04 percent. This is a 10.81 percent increase over earnings of $1.11 per…
businesswire.com LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026…
benzinga.com LivaNova Publishes Results In Neuromodulation: Technology At The Neural Interface Regarding Its CORE-VNS Trial Of Its VNS Therapy Devices LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results…- benzinga.com Barclays Initiates Coverage On LivaNova with Overweight Rating, Announces Price Target of $105 Barclays analyst Christopher Pasquale initiates coverage on LivaNova (NASDAQ:LIVN) with a Overweight rating and announces Price Target of $105.
- benzinga.com Piper Sandler Reiterates Overweight on LivaNova, Raises Price Target to $90 Piper Sandler analyst Adam Maeder reiterates LivaNova (NASDAQ:LIVN) with a Overweight and raises the price target from $87 to $90.
- benzinga.com Needham Maintains Buy on LivaNova, Raises Price Target to $93 Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $81 to $93.
- benzinga.com LivaNova Raises FY2026 Adj EPS Guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 Est; Raises FY2026 Sales Guidance from $1.445B-$1.458B to $1.499B-$1.513B vs $1.507B Est LivaNova (NASDAQ:LIVN) raises FY2026 Adj EPS guidance from $4.20-$4.30 to $4.30-$4.40 vs $4.25 analyst estimate. Raises FY2026 sales outlook from $1.445 billion-$1.458 billion to $1.499…
benzinga.com LivaNova Q2 Adj. EPS $1.26 Beats $1.10 Estimate, Sales $390.600M Beat $380.758M Estimate LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.10 by 14.55 percent. This is a 20 percent increase over earnings of $1.05 per…- benzinga.com Mizuho Maintains Outperform on LivaNova, Raises Price Target to $95 Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $90 to $95.
benzinga.com This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top Wall Street analysts changed their outlook on top names. See the latest analyst ratings and coverage on stocks like ABT, LIVN, AMPL, LION, and HONA.- benzinga.com Freedom Capital Markets Initiates Coverage On LivaNova with Hold Rating, Announces Price Target of $81 Freedom Capital Markets analyst Keith Hinton initiates coverage on LivaNova (NASDAQ:LIVN) with a Hold rating and announces Price Target of $81.
benzinga.com Keybanc Maintains Overweight on LivaNova, Raises Price Target to $92 Keybanc analyst Brett Fishbin maintains LivaNova (NASDAQ:LIVN) with a Overweight and raises the price target from $83 to $92.
benzinga.com Barclays Maintains Equal-Weight on LivaNova, Raises Price Target to $76 Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the price target from $73 to $76.- benzinga.com Mizuho Maintains Outperform on LivaNova, Raises Price Target to $90 Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $85 to $90.
- benzinga.com Baird Maintains Outperform on LivaNova, Lowers Price Target to $76 Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and lowers the price target from $78 to $76.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com Davita, Bloomin' Brands, Compass And Other Big Stocks Moving Higher On Wednesday Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised guidance. Other gaining stocks include EVC, BLMN, MNKD, FLEX, HUT, AVTX, COMP, VCYT, and SSRM.
benzinga.com LivaNova Q1 2026 Earnings Call Transcript 
benzinga.com LivaNova Raises FY2026 Sales Guidance from $1.431B-$1.445B to $1.445B-$1.458B vs $1.494B Est Full-Year 2026 GuidanceLivaNova now expects full-year 2026 revenue to grow between 7.0% and 8.0% (versus 6.0% and 7.0% prior) on a constant-currency basis. Foreign currency is expected to be a…- benzinga.com LivaNova Raises FY2026 Adj EPS Guidance from $4.15-$4.25 to $4.20-$4.30 vs $4.21 Est; Full-Year 2026 GuidanceLivaNova now expects full-year 2026 revenue to grow between 7.0% and 8.0% (versus 6.0% and 7.0% prior) on a constant-currency basis. Foreign currency is expected to be a…
- benzinga.com LivaNova Q1 Adj. EPS $0.98 Beats $0.90 Estimate, Sales $362.300M Beat $346.108M Estimate LivaNova (NASDAQ:LIVN) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.90 by 8.89 percent. This is a 11.36 percent increase over earnings of $0.88 per…
- benzinga.com LivaNova Reveals 12-Month Results From LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea; Study Demonstrates Proximal Hypoglossal Nerve Stimulation Yielded Clinically Significant Responses And Sustained Improvements Over Time LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set…
- benzinga.com LivaNova Receives FDA Premarket Approval For aura6000 System For Treatment Of Adult Patients With Moderate To Severe Obstructive Sleep Apnea – First and only hypoglossal nerve stimulation therapy approved in the U.S. without complete concentric collapse contraindication or warning language– Next-generation, MRI-compatible device expected…
- benzinga.com Barclays Maintains Equal-Weight on LivaNova, Raises Price Target to $73 Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the price target from $67 to $73.
benzinga.com 5 Analysts Assess LivaNova: What You Need To Know 
benzinga.com Needham Maintains Buy on LivaNova, Raises Price Target to $81 Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $64 to $81.- benzinga.com Earnings Scheduled For February 25, 2026
- benzinga.com LivaNova Sees FY2026 Adj EPS $4.15-$4.25 vs $4.13 Est; Sees Sales $1.471B-$1.485B vs $1.471B Est LivaNova (NASDAQ:LIVN) is looking for FY2026 Adj EPS of $4.15-$4.25 vs $4.13 analyst estimate. sees sales of $1.471 billion-$1.485 billion vs $1.471 billion analyst estimate.
benzinga.com Earnings Breakdown: LivaNova Q4 - benzinga.com LivaNova Q4 Adj. EPS $0.86 Beats $0.81 Estimate, Sales $360.900M Beat $353.312M Estimate LivaNova (NASDAQ:LIVN) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.81 by 5.52 percent. This is a 6.17 percent increase over earnings of $0.81 per…
- benzinga.com Orrum Clinical Analytics Partners With LivaNova To Connect Essenz Perfusion System To Analytics And Benchmarking Capabilities Of CŌRE Insights Platform Orrum's CŌRE Insights™ analytics platform will be available through an automatic integration for LivaNova's Essenz Perfusion SystemPLYMOUTH, Mich., Feb. 20, 2026 /PRNewswire/ -- Orrum Clinical…
- benzinga.com Barclays Maintains Equal-Weight on LivaNova, Raises Price Target to $67 Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the price target from $58 to $67.
- benzinga.com 6 Analysts Assess LivaNova: What You Need To Know
- benzinga.com Stifel Maintains Buy on LivaNova, Raises Price Target to $70 Stifel analyst Rick Wise maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $65 to $70.
- benzinga.com Keybanc Initiates Coverage On LivaNova with Overweight Rating, Announces Price Target of $81 Keybanc analyst Brett Fishbin initiates coverage on LivaNova (NASDAQ:LIVN) with a Overweight rating and announces Price Target of $81.
- benzinga.com Mizuho Maintains Outperform on LivaNova, Raises Price Target to $72 Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $70 to $72.
benzinga.com LivaNova To Present Eight Posters At AES Highlighting VNS Therapy's Seizure Reduction And Improved Outcomes In Drug-Resistant Epilepsy Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant EpilepsyLivaNova PLC (NASDAQ:LIVN), a market-leading medical…- benzinga.com Mizuho Maintains Outperform on LivaNova, Raises Price Target to $70 Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $65 to $70.
- benzinga.com Baird Maintains Outperform on LivaNova, Raises Price Target to $70 Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $63 to $70.
- benzinga.com LivaNova Announces 2030 Financial Targets, Sees High-Single-Digit-Plus Revenue CAGR; Adjusted Annual Operating Margin Above 20% Over The Next 3-Years, Targeting High Twenties By 2030; EPS CAGR In The Low Double Digits To Mid-Teens; Adjusted Free Cash Flow Conversion Above 80% Provides 2030 Targets for Revenue and EPS GrowthLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic…
benzinga.com Earnings Scheduled For November 5, 2025